|
- Diabetes lengthens the time to sputum culture conversion, as well as increasing the risk of relapse and death while on treatment.
- Diabetes may be associated with decreased rifampicin concentrations, which may result from drug–drug interactions between anti-TB drugs and oral hypoglycaemic drugs.
- Diabetes may be a risk factor for hepatic toxicity of anti-TB drugs. Thus, lower anti-TB drug concentrations and increased hepatic toxicity may lead to increased recurrent disease and death rates.
- Rifampicin consistently decreases pharmacokinetic parameters of multiple oral diabetic agents, and can impair glucose control.
- More information on diabetes and TB can be found by reading Collaborative framework for care and control of tuberculosis and diabetes.
|
